文献速递类风湿关节炎

类风湿关节炎患者经导管主动脉瓣置换术的结局观察性研究

Outcomes with transcatheter aortic valve replacement for aortic stenosis in rheumatoid arthritis: an observational study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

基于TriNetX多中心注册数据,比较合并类风湿关节炎(RA)与不合并RA的主动脉瓣狭窄患者接受经导管主动脉瓣置换术(TAVR)后的短期和长期结局。匹配后每组1374例,30天各终点无显著差异,5年死亡、卒中、心梗和住院风险亦相似,提示TAVR在RA患者中不增加额外风险。

要点

  • RA患者TAVR术后30天死亡率为2.0%,非RA组为1.5%,差异无统计学意义。
  • 5年死亡率RA组23.8%、非RA组20.5%,卒中、心梗和住院风险相似。
  • 性别亚组分析中RA患者TAVR结局无性别差异。

核心结论

  • 在大样本观察性研究中,RA患者接受TAVR未增加短期或长期不良结局风险,支持TAVR作为RA合并主动脉瓣狭窄患者的安全治疗选择。

研究设计与样本

  • 基于TriNetX研究网络的观察性研究,纳入接受TAVR的主动脉瓣狭窄患者,比较合并RA(RA+)与不合并RA(RA-)者的结局。

主要发现

  • 30天时RA+与RA-组各终点无差异,死亡率2.0% vs 1.5%(OR 1.29;95%CI 0.73-2.29)。
  • 5年死亡率23.8% vs 20.5%(OR 1.12;95%CI 0.97-1.31),卒中、心肌梗死和住院风险相似,HR与OR估计一致。
  • 在RA患者的性别分析中,结局无性别差异。

关键数值与推荐

  • 30天结局包括全因死亡、永久起搏器植入、缺血性卒中、急性肾损伤、心肌梗死、心源性休克、主要血管并发症及大出血或危及生命的出血。
  • 5年结局包括全因死亡、缺血性卒中、心肌梗死和全因住院。

临床怎么用

  • 对于合并主动脉瓣狭窄的RA患者,TAVR可作为不增加短期和长期额外风险的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the short- and long-term clinical outcomes of transcatheter aortic valve replacement (TAVR) among participants with RA and aortic stenosis compared with those without RA, using real-world data from a large multicentre registry. METHODS: Using the TriNetX Research Network, participants with aortic stenosis undergoing TAVR with (RA+) vs without (RA-) RA were identified. Odds ratios (ORs) with 95% CIs estimated 30-day all-cause mortality, permanent pacemaker implantation, ischaemic stroke, acute kidney injury, myocardial infarction, cardiogenic shock, major vascular complications, and major or life-threatening bleeding were evaluated. Five-year outcomes included all-cause mortality, ischaemic stroke, myocardial infarction and all-cause hospitalization. Cox regression was used to estimate hazard ratios (HRs) with 95% CIs. RESULTS: A total of 1414 RA+ (4.3%) and 39 004 RA- participants were eligible. After matching, 1374 were included in each cohort. At 30 days, outcomes did not differ between RA+ and RA- groups; mortality was 2.0% vs 1.5% (OR 1.29; 95% CI 0.73-2.29), with no significant differences in other endpoints. Over 5 years, mortality was 23.8% vs 20.5% (OR 1.12; 95% CI 0.97-1.31), and stroke, myocardial infarction and hospitalization were similar; HRs were concordant with OR estimates. In sex-based analyses of RA patients, outcomes did not differ by sex. CONCLUSION: In this large observational study, TAVR was not associated with excess short- or long-term risk in patients with RA. These findings support TAVR as a safe therapeutic option in RA patients with aortic stenosis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ramadan A, Doma M, Kamel I, et al. Outcomes with transcatheter aortic valve replacement for aortic stenosis in rheumatoid arthritis: an observational study. Rheumatology (Oxford). 2026. PMID: 42049908. doi:10.1093/rheumatology/keag234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。